Tuesday, May 28, 2019

PROVENGE (sipuleucel-T)

For the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

via Whats New Vaccines Blood Biologics RSS Feed http://bit.ly/30Rlx2K
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)